Previous 10 | Next 10 |
2023-07-02 09:30:00 ET Epcoritamab, a cancer drug co-developed by AbbVie (NYSE: ABBV) and Genmab (NASDAQ: GMAB) , was recently given the green light by the Food and Drug Administration to be used as a treatment for adults with relapsed or refractory (R/R) diffuse large B-cel...
2023-06-29 10:05:50 ET Summary Genmab's stock has seen negative price action despite the FDA approval of its drug, Epcoritamab, for relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The market has already priced in the approval, and the drug faces a competitive landscape ...
Company Announcement Based on the topline results from the EPCORE™ NHL-1 clinical trial, Genmab and AbbVie will engage with global regulatory authorities to discuss next steps Data from the clinical trial will be presented at a future medical meeting Follicular Ly...
Genmab A/S (Nasdaq: GMAB) today announced that epcoritamab, a T-cell engaging bispecific antibody, has been added to the National Comprehensive Cancer Network ® (NCCN ® ) Clinical Practice Guidelines in Oncology (NCCN Guidelines ® ) for “B-cell Lymphomas...
Results from phase 1/2 EPCORE™ NHL-2 trial investigating epcoritamab in combination with rituximab-lenalidomide (R2) showed a 98 percent overall response rate (ORR), 87 percent complete metabolic response (CMR) in patients with relapsed or refractory (R/R) follicular lymphoma (FL) ...
2023-05-29 06:15:24 ET Summary Shares of antibody drug conjugate concern ADC Therapeutics SA are down 95% from their all-time high set in mid-2020 as tepid upside to Zynlonta sales and Cami program uncertainty. The company does have two licensing deals inked for Zynlonta and is se...
Oral presentations will highlight epcoritamab-bysp in combination with rituximab-lenalidomide (R2) in high-risk follicular lymphoma Poster presentations will highlight epcoritamab in lymphoma across multiple lines of therapy and histologies where high unmet needs exist Gen...
2023-05-19 12:59:30 ET AbbVie ( NYSE: ABBV ) and Genmab A/S ( GMAB ) announced Friday that the FDA approved Epkinly, a bispecific antibody therapy, as a late-line option for adults with white blood cell cancer large B-cell lymphoma (DLBCL). Specifically, the FDA’s l...
Company Announcement Results from phase 2 clinical trial demonstrated EPKINLY ™ (epcoritamab- bysp ) delivered 61 percent overall response rate , 38 percent complete response, and 15. 6 -month median duration of response in ...
2023-05-11 08:25:47 ET Polar Power ( POLA ) +66% now taking pre-orders for new line of mobile EV chargers, stock jumps 52%. MMTec ( MTC ) +24% . Home Point Capital ( HMPT ) +18% to acquire Home Point Capital for $324M in cash. AppLovin Corporation ( A...
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States Innovative Eyewear Inc. (LUCY) rose 78.0% to $0.58749 on volume of 130,454,575 shares Ocean Power Technologies Inc. (OPTT) rose 29.6% to $0.2073 on volume of 51,927,154 shares Cosmos Health Inc. (COSM) rose 64.9% to $1.12 on volume of...
Company Announcement Positive CHMP opinion based on results from the Phase 1/2 EPCORE ® NHL-1 study FL is the second most common type of NHL and accounts for approximately 20-30 percent of all global cases If approved, epcoritamab (TEPKINLY ® ...
2024-06-27 09:00:08 ET Kaveri Pohlman from BTIG issued a price target of $47.00 for GMAB on 2024-06-27 07:34:00. The adjusted price target was set to $47.00. At the time of the announcement, GMAB was trading at $25.67. The overall price target consensus is at $41.80 with...